LONGITUDINAL CHANGES IN MEDICATION DOSING AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: FROM THE CHAMP-HF REGISTRY

Stephen J. Greene,Gregg C. Fonarow,Adam D. DeVore,Puza P. Sharma,Muthiah Vaduganathan,Nancy M. Albert,Carol I. Duffy,C. Larry Hill,Kevin McCague,J. Herbert Patterson,John A. Spertus,Laine Thomas,Fredonia B. Williams,Adrian F. Hernandez,Javed Butler

LONGITUDINAL CHANGES IN MEDICATION DOSING AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: FROM THE CHAMP-HF REGISTRY

2019

Stephen J. Greene
Gregg C. Fonarow
Adam D. DeVore
Puza P. Sharma
Muthiah Vaduganathan
Nancy M. Albert
Carol I. Duffy
C. Larry Hill
Kevin McCague
J. Herbert Patterson
John A. Spertus
Laine Thomas
Fredonia B. Williams
Adrian F. Hernandez
Javed Butler

Guidelines recommend titration of medical therapy for heart failure with reduced ejection fraction (HFrEF) to target doses derived from clinical trials, as tolerated. The degree to which such titration occurs in contemporary US practice is unclear. Among 2,588 US outpatients with chronic HFrEF in

Keywords:

Dosing
Cardiology
Internal medicine
Ejection fraction
Heart failure
Diabetes mellitus
Medicine
Clinical trial
medical therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations